VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy 2017 | Which is the best combination therapy in relapsed and refractory multiple myeloma?

Meletios Dimopoulos, MD, from the Athens School of Medicine, Athens, Greece, discusses combination therapies for relapsed and refractory myeloma treatment at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He describes the most commonly used combinations for patients with aggressive relapse and elderly patients. Prof. Dimopoulos highlights the importance of determining if patients are refractory to particular treatments such as bortezomib or lenalidomide, in which case different regiments could be used.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter